Azitra (AZTR) Stock Price, News & Analysis

Company Overview

Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.

Key Stats

• Today's Range: $0.41 to $0.57
• 50-Day Range: N/A
• 52-Week Range: $0.35 to $68.40
• Volume: 9.96 million shs
• Average Volume: 5.58 million shs
• Market Capitalization: $3.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Azitra Stock Analysis - MarketRank™

Azitra scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Azitra.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Azitra are expected to grow in the coming year, from ($2.78) to ($0.95) per share.

Price to Book Value per Share Ratio

Azitra has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.72% of the float of Azitra has been sold short.

Short Interest Ratio / Days to Cover

Azitra has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Azitra has recently increased by 96.02%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Azitra does not currently pay a dividend.

Dividend Growth

Azitra does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.72% of the float of Azitra has been sold short.

Short Interest Ratio / Days to Cover

Azitra has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Azitra has recently increased by 96.02%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -1.00

News Sentiment

Azitra has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Azitra this week, compared to 1 article on an average week.

Search Interest

1 people have searched for AZTR on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Azitra insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.57% of the stock of Azitra is held by insiders.

Percentage Held by Institutions

Only 11.16% of the stock of Azitra is held by institutions.

AZTR Stock Analysis - Frequently Asked Questions

How were Azitra's earnings last quarter?

Azitra, Inc. (NYSEAMERICAN:AZTR) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.31.

When did Azitra's stock split?

Azitra's stock reverse split on Monday, July 1st 2024. The 1-30 reverse split was announced on Monday, July 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Azitra?

Shares of AZTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Azitra own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Azitra investors own include NVIDIA (NVDA), Broadcom (AVGO), Tesla (TSLA), Advanced Micro Devices (AMD), CrowdStrike (CRWD), FedEx (FDX) and Intel (INTC).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 1/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:AZTR
• CUSIP: N/A
• CIK: 1701478
• Web: azitrainc.com
• Phone: 203-646-6446
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-11,280,000.00
• Net Margins: N/A
• Pretax Margin: -9,232.35%
• Return on Equity: -212.16%
• Return on Assets: -145.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.58
• Quick Ratio: 5.58

Sales & Book Value

• Annual Sales: $690,000.00
• Price / Sales: 4.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.23 per share
• Price / Book: 0.06

Miscellaneous

• Outstanding Shares: 7,630,000
• Free Float: 7,583,000
• Market Cap: $3.20 million
• Optionable: Not Optionable
• Beta: -1.33